Hongyan Wang PhD
Hongyan Wang PhD
440 BRT 460 W 12th Ave Columbus OH 43210
- Experimental Therapeutics
General Research InterestMy major research interest is to understand the molecular mechanisms underlying the anti-cancer effects of small-molecule agents and microRNA; and establish their pharmacokinetic-pharmacodynamic correlation in rodent models of acute myeloid leukemia.
Research DescriptionWe are currently performing pre-clinical testing of synthetic microRNAs with the goal of moving them into the clinical trials and eventually developing them as cancer therapeutics. A second research area is to elucidate novel mechanisms of actions of nucleoside analogs. Information from these studies will provide basis for new drug combinations for cancer therapy.
Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15(1) 242-9 1/1/2013
Wang H, Chiu M, Xie Z, Chiu M, Liu Z, Chen P, Liu S, Byrd JC, Muthusamy N, Garzon R, Croce CM, Marcucci G, Chan KKSynthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.Mol Pharm 9(6) 1638-44 6/4/2012
Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci G, Chan KKRNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.Blood 119(22) 5229-38 5/31/2012
© The Ohio State University